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ABSTRACT: Arthritic diseases are disabling conditions
aﬀecting millions of patients worldwide. Pro-inﬂammatory
cytokines, particularly interleukin-6 (IL-6), plays a crucial role
in inﬂammation and cartilage destruction. Although the
beneﬁcial eﬀects of antibody therapy, its eﬃcacy is limited.
Therefore, this work proposes the immobilization of antibodies
at the surface of biodegradable polymeric nanoparticles (NPs)
to capture and neutralize IL-6. Our system is intended to
protect, extend and enhance the therapeutic eﬃcacy after
delivery. Chitosan−hyaluronic acid NPs are synthesized as a
stable monodisperse population. After determining the
maximum immobilization capacity (10 μg/mL), the capture ability was conﬁrmed. Biological assays demonstrate the NPs
cytocompatibility with human articular chondrocytes (hACs) and human macrophages. hACs stimulated with macrophage
conditioned medium shows the beneﬁcial role of IL-6 capture and neutralization. Biofunctionalized NPs exhibit a prolonged
action and stronger eﬃcacy than the free antibody. In conclusion, this system can be an eﬀective and long lasting treatment for
arthritic diseases.
KEYWORDS: arthritic diseases, pro-inﬂammatory cytokine interleukin-6, biodegradable polymeric nanoparticles,
anti-IL-6 antibody immobilization, IL-6 capture and neutralization
■ INTRODUCTION
Arthritic diseases are inﬂammatory joint disorders, associated
with synovitis and articular cartilage destruction. The most
common forms of arthritis are osteoarthritis (OA) and
rheumatoid arthritis (RA).1 OA, a local degenerative joint
disease, is the leading cause of morbidity and disability in the
elderly, aﬀecting around 10% of men and 18% of women over
60 years of age.2 In contrast to OA, RA is a systemic
autoimmune disease that usually involves multiple joints,
aﬀecting 0.3−1.0% of the general population.2
Even though joint damage in OA and RA proceeds via
diﬀerent pathways, in both the normal balance of extracellular
matrix (ECM) is disrupted and shifts toward degradation.3
Cartilage disruption is associated with an increase of the levels
of pro-inﬂammatory cytokines such as tumor necrosis factor-α
(TNF-α) and interleukins (IL, particularly IL-1β and IL-6),
mainly produced by mononuclear cells, chondrocytes or
synoviocytes.1 These cytokines increases the production of
catabolic factors and down-regulates the anabolic mediators.4,5
Hence, pro-inﬂammatory cytokines up-regulates injurious
enzymes, especially matrix metalloproteinases. Simultaneously,
they inhibit the production of their physiological regulators,
stimulate the production of nitric oxide, and hinder the
synthesis of ECM components such as collagen type II and
aggrecan.
IL-6 is a key mediator in the pathophysiology of OA and RA,
as it regulates a wide range of fundamental biological activities,
including acute-phase responses, inﬂammation, and immune
responses.6 Indeed, OA and RA patients present high
concentrations of this pleiotropic cytokine,7 and many eﬀorts
are being made to create biosensors to monitor IL-6 secretion
in vivo.8 In addition, higher levels of IL-6 in OA was found to
be a signiﬁcant predictor of superior risk of cartilage loss and
reduced response to treatment.9 Thus, strategies targeting IL-6
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or its receptors are promising treatments for arthritis diseases.10
The ﬁrst humanized anti-IL-6 receptor antibody, tocilizumab,
has demonstrated its outstanding clinical eﬃcacy and tolerable
safety proﬁle in phase III clinical trials for RA patients, resulting
in its worldwide approval to treat moderate-to-severe active RA.
This successful approach led to the development of other IL-6
inhibitors, including fully human anti-IL-6 receptor mAb
(sarilumab, sirukumab, and olokizumab).11 This cytokine is
being also considered the most interesting new target for OA
treatment with clinical trials currently in progress
[ClinicalTrials.gov Identiﬁer: NCT02477059].
Although these treatments seem very attractive, systemic
injection of biological agents are associated with serious side
eﬀects, such as risk of infection, administration reactions,
congestive heart failure, demyelinating diseases, hyperlipidemia,
among other conditions that aﬀect patient health.12 In this
sense, intra-articular (IA) injections oﬀers several beneﬁts by
achieving high local bioavailability, reducing systemic exposure
and requiring lower doses.13,14 However, because of the rapid
clearance of antibodies by the synovium, the therapy has
limited eﬃcacy. Hence, there is an unmet need for the
development of new eﬀective approaches, with prolonged
eﬃcacy and reduced side eﬀects.
Nanoparticles (NPs) are promising approaches to solve
limitations of conventional therapies.14 The unique properties
of NPs make them highly attractive for the design of novel
modalities for arthritis treatment. Nanoscale features can be
used to protect the therapeutic agent from degradation and to
have targeted and controlled delivery, which improves drug
eﬃcacy, reduces the dosage and signiﬁcantly reduces the side
eﬀects. Actually, polymeric NPs are one of the most studied
strategies for nanomedicine.15 Polymers are widely used as
building blocks, due to the ﬂexible design based on
functionalization, macromolecular synthesis methods, and
polymer diversity. Regarding degradation properties, biode-
gradable polymeric NPs are highly preferred for medical
applications, providing outstanding bioavailability, stability,
compatibility and controlled release.16 In this work, natural-
derived polymers were used, namely, chitosan (Ch) and
hyaluronic acid (HA). They possess a high level of functional
groups, such as amino (NH2) and carboxylic acid (COOH)
groups, that can be further modiﬁed and functionalized with
other polymers, cross-linkers, or biomolecules.17,18 Ch, the
second most abundant polysaccharide in nature, is particularly
attractive due to its advantages, such as noncytotoxicity, low
immunogenicity, high stability, and reasonable cost.19,20
Although there are some studies reporting Ch as vaccine
adjuvant,21 the capacity to promote cellular immunity is related
with the deacetylation degree of the polymer.22 Indeed the
deacetylation degree and immunogenicity are inversely
correlated in this biomaterial. Therefore, in this work, Ch
with a high degree of deacetylation was used to avoid any
immunogenicity. HA is a natural component of the ECM of
articular cartilage and synovial ﬂuid. Because of the interaction
with CD44 receptors of the cells, especially chondrocytes, HA
plays an important role on cartilage function.23 Nonetheless,
HA physicochemical and biological properties depend on its
molecular weight (MW).24 High MW HA displays anti-
inﬂammatory and immune-suppressive properties, whereas
low MW HA is a potent pro-inﬂammatory molecule. It has
been reported that HA with MW of 700−6000 kDa are the best
suited for cartilage repair.19
The aim of this study was to develop a carrier intended for IA
administration and allowing the capture and neutralization of
IL-6, a crucial pro-inﬂammatory mediator in arthritic joints
(Scheme 1). Ch and HA were used to produce biofunction-
Scheme 1. Schematic Illustration of the Biofunctionalized NPs Role in Arthritis Treatment: (A) Production of the
Biofunctionalized Polymeric NPs and (B) Inﬂammation Reduction in the Synovial Fluid after the Neutralization of IL-6 by the
NPsa
aAbbreviations: Ch, chitosan; HA, hyaluronic acid; EDC, ethyl-3-(3-(dimethylaminopropyl)carbodiimide; NHS, N-hydroxysuccinimide.
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alized NPs with anti-IL-6 antibody immobilized at NPs’ surface.
The maximum immobilization of antibody and the capture
capability was assessed. NPs cytocompatibility was validated by
their culturing with human articular chondrocytes (hACs) and
human macrophages. Our system was also validated by
stimulating hACs with macrophage conditioned medium, and
then treating with biofunctionalized NPs or the free antibody.
Considering the drawbacks of the current treatments, we
hypothesized that this strategy oﬀers a maximum therapeutic
eﬀect of the immobilized antibodies, avoiding unnecessary
exposure to healthy tissues and systemic side-eﬀects.
■ EXPERIMENTAL SECTION
Materials. Ch with a MW of 150 kDa and 95% of deacetylation
degree was purchased from Heppe Medical Chitosan GmbH
(Germany). HA with a MW of 750 kDa was bought from Lifecore
Biomedical (USA). Mouse monoclonal anti-IL-6 antibody and human
IL-6 full length protein was purchased from Abcam (UK). Alexa Fluor
594 donkey antimouse IgG, Roswell Park Memorial Institute (RPMI)-
1640 media and Fetal Bovine Serum (FBS) were purchased from
Thermo Fisher Scientiﬁc (USA). Human IL-6 Standard ABTS ELISA
Development Kits and human Fibroblast Growth Factor (bFGF) was
acquired from Peprotech (USA). CD14 MicroBeads and recombinant
human granulocyte macrophage colony-stimulating factor (GM-CSF)
was obtained from Miltenyi Biotec (USA). All other reagents were
purchased from Sigma-Aldrich (USA).
NPs Preparation. Ch-HA NPs were prepared by polyelectrolyte
complexation of both natural-based polyelectrolytes. Brieﬂy, Ch was
dissolved in 1% (v/v) acetic acid, while HA was dissolved in ultrapure
water, overnight at room temperature. Both solutions were ﬁltered
through a 0.22 μm pore membrane. The NPs formation occurred
spontaneously when the HA solution was added dropwise at 1 mL/
min rate to the Ch solution under strong magnetic stirring (600 rpm).
Diﬀerent initial polymers concentration (0.25, 0.5, and 1 mg/mL) and
pH values (3, 4, 5, 6 and 7) were used to evaluate the inﬂuence of
these parameters on the properties of the NPs.
During preparation, NPs were stabilized through carbodiimide
chemistry. 1-ethyl-3-(3-(dimethylaminopropyl)carbodiimide (EDC)/
N-hydroxysuccinimide (NHS) reagents were dissolved in 0.1 M MES
buﬀer (pH 4.7) with 0.9% (w/w) NaCl. Five diﬀerent EDC/NHS
ratios were tested, namely 400/100, 100/400, 200/200, 50/200, and
200/50 mM.
For ﬂuorescence biological assays, 200 μL of ﬂuorescein
isothiocyanate (FITC, 2 mg/mL in ethanol/water, 1:10) was added
to the Ch solution before the NPs formation.
To remove unreacted compounds, the NPs were washed twice with
ultrapure water by centrifugation (30 min, 4000 rpm at 20 °C) using
Vivaspin 300 kDa Filter Units (Fisher Scientiﬁc). To avoid NPs
aggregation, glucose at 2 mg/mL was added before centrifugation.25
NPs Characterization. Size Distribution and Zeta Potential
Measurements. The size and polydispersity index (PDI) of the
produced NPs were assessed by dynamic light scattering (DLS) and
the zeta potential was determined by laser Doppler microelectropho-
resis using a Zetasizer Nanoseries ZS equipment (Malvern Instru-
ments, Portugal). The measurements were performed at 25 °C using
samples diluted in ultrapure water (1:20; v/v).
Stability Studies. For pH stability assessment, the pH was increased
until 7.4 using NaOH 1 M. For storage stability, the NPs suspensions
were kept at 4 °C under static conditions. During the experimental
time (6 months), it was determined the size, PDI and zeta potential, as
just described.
NPs Morphology. Morphological analysis of the developed Ch-HA
NPs was performed by scanning electron microscopy (SEM) and
atomic force microscopy (AFM). Prior to analysis, Ch-HA NPs were
diluted in water (1:20; v/v) and disposed into the surface of a glass
slide for air-dry. For SEM analysis, the NPs were sputter-coated with
palladium (EM ACE600, LEICA) and analyzed using High-Resolution
Field Emission Scanning Electron Microscope (Auriga Compact,
ZEISS). AFM measurements were performed using a MultiMode
STM microscope controlled by a NanoScope III from Digital
Instruments system, operating in tapping mode at a frequency of 1 Hz.
Antibody Immobilization Determination. The anti-IL-6 antibody
was immobilized at the surface of the optimized Ch-HA NPs. To
determine the NPs’ maximum immobilization capacity, a range of
primary antibody concentrations were tested (from 5 to 20 μg/mL).
First, the anti-IL-6 antibody was activated with a solution of 50/200
mM EDC/NHS in 0.1 M MES buﬀer for 15 min. Then, the NPs were
incubated with the activated anti-IL-6 antibody, overnight at 4 °C. To
remove the unbound antibody, the biofunctionalized NPs were washed
twice by centrifugation, as previously described.
To determine the degree of anti-IL-6 antibody immobilization, the
biofunctionalized NPs were incubated with the secondary antibody
Alexa Fluor 594 solution for 1 h at room temperature. As negative
control, NPs without immobilized antibody were used (0 μg/mL).
After centrifugation, the ﬂuorescence of the unbound secondary
antibody (in supernatant) were determined using an excitation−
emission wavelengths of 590/20−645/40 nm, respectively, in a
microplate reader (Synergie HT, Bio-Tek). The concentration of the
anti-IL-6 antibody at the NPs surface corresponds to the diﬀerence
between the initial and unbound secondary antibody.
IL-6 Capturing. Ch-HA NPs biofunctionalized with anti-IL-6
antibody (5−20 μg/mL) were incubated with 1.25 μg/mL of human
IL-6 full length protein, overnight at room temperature. After
centrifugation, the supernatants were collected and the unbound IL-
6 was assessed using the ELISA Development Kit. The amount of IL-6
captured by the biofunctionalized NPs corresponds to the diﬀerence
between the initial and unbound amount of the added cytokine.
Biological Assays. Isolation and Cell Culture. hACs were isolated
from knee cartilage samples collected from arthroplasties surgeries
biopsies. Samples were obtained through the cooperation agreement
between Centro Hospitalar do Alto Ave, Guimaraẽs, Portugal, and
3B’s Research Group, and after informed donor consent. Cells were
isolated by enzymatic digestion, according to a previously described
protocol.26 hACs cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM), supplemented with 10% FBS, 10 mM HEPES
buﬀer, L-lanyl-L-glutamine, MEM nonessential amino acids, 100 units/
mL of penicillin, 100 μg/mL of streptomycin, and 10 ng/mL human
bFGF, and incubated at 37 °C in a humidiﬁed 5% CO2 atmosphere.
The human monocytic cell line THP-1 was maintained in complete
RPMI, containing RPMI-1640 media supplemented with 2 mM L-
glutamine, 100 units/mL of penicillin, 100 μg/mL of streptomycin, 10
mM HEPES buﬀer, and 10% FBS.
Human monocyte-derived macrophages were generated from
peripheral blood mononuclear cell (PBMCs). Buﬀy coats from healthy
donors were obtained after written informed consent at the Hospital
de Braga, Braga, Portugal. Brieﬂy, PBMCs were enriched from buﬀy
coats by density gradient using Histopaque-1077. Cells present in the
enriched mononuclear fraction were washed twice in PBS and
resuspended in RPMI-1640 culture medium with 2 mM glutamine and
2 g/L NaHCO3 supplemented with 10% human serum, 100 units/mL
of penicillin, 100 μg/mL of streptomycin, and 10 mM HEPES buﬀer.
Monocytes were then separated by positive selection using magneti-
cally labeled CD14 MicroBeads on a MiniMACS separator. Isolated
monocytes were resuspended in complete RPMI medium and seeded
at a concentration of 106 cells/mL in 24-well plates for 7 days in the
presence of 20 ng/mL of GM-CSF. Acquisition of macrophage
morphology was conﬁrmed by visualization in a BX61 microscope
(Olympus, Japan).
Cell Seeding. For hACs seeding, cells (5 × 104 cells/mL) were
added to tissue culture polystyrene (TPCS) coverslips in 24-well
plates. After cell attachment during 5 h, culture medium was added to
a ﬁnal volume of 1 mL. Diﬀerent concentrations of sterilized Ch-HA
NPs were added to hACs subsequently to 24 h of incubation. NPs
were sterilized by UV treatment for 30 min.
For the induction of THP-1 cell diﬀerentiation, cells (106 cells/mL)
were seeded in cRPMI with 100 nM phorbol 12-myristate-13-acetate
(PMA) for 24 h. After incubation, nonattached cells were removed by
aspiration, and the adherent cells were washed three times with
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cRPMI. To ensure reversion of cells to a resting macrophage
phenotype before stimulation, cells were incubated for an additional
48 h in cRPMI without PMA. For stimulation and retrieval of
conditioned media, cells were further incubated for 24 h with 100 ng/
mL of lipopolysaccharide in fresh media and the supernatants were
collected and stored at −80 °C. IL-6 production by cells was assessed
in the supernatants by commercial ELISA. Then, Ch-HA NPs were
added at diﬀerent concentrations.
Regarding the human primary macrophages, after 7 days in the
presence of GM-CSF, culture medium was replaced and diﬀerent
concentrations of Ch-HA NPs were added.
Cells cultured without NPs (only with culture medium) were used
as control. After 1, 2, 3, and 7 days of culture with NPs, the diﬀerent
samples in triplicate were washed with sterile PBS and analyzed
regarding cell viability (MTS assay), cell proliferation (DNA
quantiﬁcation), total protein synthesis and SEM analyses.
Cell Viability. The metabolic activity of cells treated or not with
diﬀerent concentrations of Ch-HA NPs was determined by MTS assay
(CellTiter 96 Aqueous One Solution, Promega), according to the
instructions of the manufacturer. Brieﬂy, a mixture of culture medium,
without FBS and phenol red, and MTS reagent (5:1 volume ratio)
were added to each well. Samples were incubated for 3 h at 37 °C in a
humidiﬁed 5% CO2 atmosphere. The absorbance was read in triplicate
at 490 nm, using a microplate reader (Synergie HT, Bio-Tek).
Cell Proliferation. Cell proliferation was assessed using a
ﬂuorimetric dsDNA quantiﬁcation kit (Quant-iT, PicoGreen, Molec-
ular Probes, Invitrogen). First, cell samples were transferred to
Eppendorf tubes containing 1 mL of ultrapure water and frozen at −80
°C until further analysis. Prior to DNA quantiﬁcation, samples were
defrosted and sonicated for 15 min. DNA standards were prepared at
concentrations ranging from 0 to 2 μg/mL in ultrapure water. To each
well of a white opaque 96-well plate (Falcon) were added 28.7 μL of
sample or standard (n = 3), 71.3 μL of PicoGreen solution, and 100
μL of Tris-EDTA (TE) buﬀer. The plate was incubated for 10 min in
the dark, and the ﬂuorescence of each sample was measured in a
microplate reader (Synergie HT, Bio-Tek), using an excitation
wavelength of 485 nm and an emission wavelength of 528 nm.
DNA concentration of the samples was inferred from the standard
curve.
Total Protein. Total protein content was quantiﬁed using a Micro
BCA protein assay kit (Pierce, Thermo Scientiﬁc), according to the
manufacturer’s instructions. Brieﬂy, samples were collected in triplicate
as described above. Standards were prepared in ultrapure water in
concentrations ranging from 0 to 40 μg/mL. Then, 150 μL of samples
or standards in triplicate and 150 μL of working reagent were added to
each 96-well plate. The plate was sealed and incubated for 2 h at 37
°C. Then, the absorbance was measured at 562 nm using a microplate
reader (Synergie HT, Bio-Tek). Protein concentration was inferred
from the standard curve.
SEM Analyses. SEM was used to analyze the morphology of cells in
the presence of Ch-HA NPs. Brieﬂy, cells were ﬁxed with 2.5%
glutaraldehyde and kept at 4 °C. Dehydration was performed using
increasing concentrations of ethanol (10%, 20%, 40%, 60%, 80%, 90%,
95%, and 100%). Then, the samples were sputter-coated (EM
ACE600, LEICA) with a thin layer (8−12 nm) of palladium and
analyzed by High-Resolution Field Emission Scanning Electron
Microscope (Auriga Compact, ZEISS). Microphotographs were
recorded at 5 kV with magniﬁcations of 200, 1000, and 10000×.
NPs Internalization. For internalization assays, hACs were seeded
at a concentration of 20 000 cells per well on μ-slides (Ibidi) for
Figure 1. (A) Particle size and PDI of Ch-HA NPs obtained for diﬀerent initial concentrations of Ch and HA, at pH 5. (B) Inﬂuence of EDC/NHS
concentration on the particle size at pH 5 and 7.4. (C) Stability evaluation of NPs kept in water at 4 °C for 6 months. (D) SEM and (E) AFM
micrographs of the produced Ch-HA NPs.
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confocal microscopy analysis. Ch-HA NPs functionalized or not with
the anti-IL-6 antibody were added at a concentration of 50 μg/mL to
the cultured cells. After 12 h, cells were ﬁxed with 10% formalin in PBS
and stored at 4 °C. Then, samples were stained (between each step
samples were washed three times with PBS): 1) cell membranes were
permeated with Triton X-100 (0.2%) for 5 min; 2) nonspeciﬁc
proteins were blocked with 3% bovine serum albumin for 30 min; 3)
the cytoskeleton was staining with phalloidin (0.25 μg/mL) and cell
nuclei labeled with DAPI (1 μg/mL) during 15 min. Images of
ﬂuorescent-labeled cells and NPs were obtained by using excitation
wavelengths of 405 nm (DAPI), 488 nm (FITC labeled NPs) and 561
nm (phalloidin). Images were acquired using a laser scanning confocal
microscopy imaging system (TCS SP8, Leica).
Biofunctionalized NPs Capturing Ability of IL-6. hACs were
seeded as previously described. After cell attachment, hACs were
stimulated for 24 h with monocyte-derived macrophage conditioned
medium containing 500 pg/mL of IL-6. hACs cultured without
macrophage conditioned medium (only culture medium) were used as
controls. Three diﬀerent conditions were tested: (1) no treatment, (2)
treatment with biofunctionalized NPs presenting a concentration of
anti-IL-6 antibody equal to 1 μg/mL, and (3) treatment with soluble
anti-IL-6 antibody at a concentration of 1 μg/mL. After 1, 3, 7, and 14
days, samples were collected and evaluated regarding cell viability,
proliferation, total protein synthesis and SEM analysis as previously
described. The amount of IL-6 in the supernatants was assessed by
ELISA. During the time of experiment 300 μL of fresh media was
added each 3 days, but no media was removed to keep the NPs and
the conditioned media in contact with the cells.
IL-6 Quantiﬁcation. For the quantiﬁcation of the IL-6, human
sandwich IL-6 ELISA Kit was performed according to the
manufacturer procedure. ABTS liquid substrate was added to each
well and color development was assessed by measuring the absorbance
at 405 and 650 nm, in a microplate reader (Synergie HT, Bio-Tek).
The IL-6 concentration was inferred from the standard curve.
Statistical Analyses. Data are presented as the mean ± standard
deviation of at least three independent assays. Statistical analyses were
performed using GraphPad Prism Software. First, a Shapiro−Wilk test
was used to establish the assumption of data normality. Since data not
followed a normal distribution, a nonparametric test was used
(Kruskal−Wallis test) followed by Dunn’s test. P < 0.01 was
considered statistically signiﬁcant.
■ RESULTS
Characterization of Ch-HA NPs. Ch-HA NPs were
successfully prepared by polyelectrolyte complexation. The
inﬂuence of the initial polymer concentration and pH values on
size, PDI and zeta potential of Ch-HA NPs are shown in Figure
1A and Table 1, respectively. Both particle size and PDI
increased with the increase of the concentration of Ch and HA
polymers, within a linear range relationship. Concerning the
aim of this study, it was selected the condition that originates
smaller NPs (0.25 mg/mL) to obtain a higher surface area for
enlarged biofunctionalization. Regarding the inﬂuence of pH
(Table 1), it can be inferred that the initial pH of Ch solution
has a huge inﬂuence on particle size and PDI, in contrast with
the initial pH of HA solution. The same behavior was observed
for zeta potential measurements. The initial pH of the Ch
solution has a signiﬁcant impact on the zeta potential,
presenting a higher value at pH 5. The pH of the HA solution
has no impact over the zeta potential, but higher values were
also found for a pH value of 5. Since we aimed to produce
monodisperse NPs with higher stability, we selected pH 5 for
both Ch and HA solutions. Additionally, it was observed that
adding glucose to the NPs suspension before centrifugation
avoids their aggregation (121.8 ± 2.4 nm, 0.11 ± 0.01 of PDI
and 178.8 ± 51.1 nm, 0.24 ± 0.08 of PDI in the presence or in
the absence of glucose, respectively, after centrifugation).
Although the Ch-HA NPs were stable in water, the particle
size and PDI increased at pH 7.4. In order to increase the NPs
stability at physiological pH, carbodiimide chemistry (EDC/
NHS) was tested. As shown in Figure 1B, the optimal
concentrations of EDC/NHS for stabilization were 50 mM/
200 mM, since it is required lower concentrations of reagents to
have the same eﬀect over NPs size distribution.
Storage stability was also assessed, and as shown in Figure 1C
the produced NPs were stable during time without a signiﬁcant
increase of size and PDI for at least 6 months.
From SEM and AFM analyses (Figure 1D and E,
respectively), it was possible to observe that Ch-HA NPs
presented a spherical shape with dimensions around 130 nm,
which is in agreement with the DLS measurements.
Optimization of Antibody Immobilization at the NPs
Surface. Anti-IL-6 antibody was covalently immobilized at the
NPs surface using the same chemistry previously described. To
quantify the amount of primary antibody immobilized at the
NPs surface, an indirect method was used, based on the
measurement of the ﬂuorescence of the unbound secondary
antibody (Figure 2). Higher ﬂuorescence values of secondary
antibody correspond to lower concentrations of immobilized
anti-IL-6 antibody. As can be observed in Figure 2,
concentrations above 10 μg/mL displayed signiﬁcantly lower
values of ﬂuorescence intensity than control (0 μg/mL).
Moreover, these concentrations did not display signiﬁcantly
diﬀerences between them. Therefore, the maximum immobi-
lization capacity of anti-IL-6 antibody is 10 μg/mL. After this
Table 1. Inﬂuence of pH Values on the Diameter,
Polydispersity Index (PDI), and Zeta Potential of Ch-HA
NPsa
solution pH
Ch HA size (nm) PDI zeta potential (mV)
3 859.1 ± 427.6 0.66 ± 0.26 5.77 ± 0.58
4 1134.0 ± 139.1 0.16 ± 0.19 7.10 ± 2.24
5 5 121.8 ± 2.4 0.11 ± 0.01 25.12 ± 1.86
6 430.5 ± 82.6 0.31 ± 0.18 5.87 ± 4.43
7 3337.0 ± 640.4 0.78 ± 0.31 −19.68 ± 3.31
5 4 128.2 ± 13.5 0.20 ± 0.04 16.33 ± 2.40
6 121.3 ± 6.7 0.19 ± 0.04 16.96 ± 5.38
7 117.8 ± 4.29 0.17 ± 0.08 18.00 ± 0.99
aThe pH of the solutions used to produce the selected NPs are
highlighted in the table.
Figure 2. Box plot of anti-IL-6 antibody immobilization at 0 to 20 μg/
mL concentrations. Asterisk (*) denotes signiﬁcant diﬀerences (p <
0.01) compared to control (0 μg/mL).
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point, the NPs surface becomes saturated and the ﬂuorescence
intensity reaches a plateau.
Afterward antibody immobilization, the biofunctionalized
NPs presented 132.05 ± 2.58 nm of diameter, 0.12 ± 0.01 of
PDI and +20.07 ± 2.10 mV of zeta potential. Additionally, the
NPs remained stable.
Capture of IL-6. To conﬁrm the ability of the primary anti-
IL-6 antibody immobilized at the NPs’ surface to capture and
neutralize IL-6, a human full length recombinant IL-6 protein
was added at 1.250 μg/mL to the biofunctionalized NPs. The
amount of unbound IL-6 determined in NPs without
functionalization (Table 2) revealed their ineﬀectiveness of
capturing IL-6. For biofunctionalized NPs, the maximum
capture (1.222 ± 0.020 μg/mL) was achieved with an initial
antibody concentration of 10 μg/mL, which comprises around
98% of capture. No signiﬁcant diﬀerences were found for higher
initial concentrations of anti-IL-6 antibody.
Biological Assays. NPs Cytocompatibility. To use Ch-HA
NPs as a platform of antibody carrying to treat arthritic
diseases, it was performed an assessment of their potential
toxicity for: (1) hACs, (2) human monocyte-like cell line,
THP-1, and (3) human primary macrophages. hACs isolated
from diseased knee arthroplasties have a phenotype associated
with arthritic diseases, being a relevant model to assess any
toxic interaction. Macrophages were also used since they
represent a suitable model to assess the cytocompatibility of
NPs with the immune system.
Diﬀerent biological assays were conducted to assess cell
viability (MTS assay), proliferation (DNA quantiﬁcation), total
protein synthesis and morphology (SEM) after 1, 2, 3, and 7
days of culture.
For hACs a wide range of NPs concentration (10−500 μg/
mL) was tested. Even though cell viability (Figure 3A) was not
aﬀected, considering the cell proliferation at NPs concen-
trations above 50 μg/mL, there was a signiﬁcantly decrease
compared to the control. Nonetheless, SEM analyses conﬁrm
that the cell morphology was not aﬀected by NPs (Figure 4A).
From these results, we can infer that the maximum NPs
concentration that does not have a harmful eﬀect to the cells is
50 μg/mL. For NPs internalization assessment, hACs were
exposed during 12 h to NPs, subjected or not to











0 1.245 ± 0.025
5 0.068 ± 0.007 1.182 ± 0.007 94.56 ± 0.56
10 0.028 ± 0.020 1.222 ± 0.020 97.79 ± 1.6
15 0.067 ± 0.017 1.183 ± 0.017 94.64 ± 1.36
20 0.057 ± 0.018 1.193 ± 0.018 95.44 ± 1.44
Figure 3. Biological performance of the (A) hACs, (B) THP-1 cell line, and (C) primary human macrophages cultured with diﬀerent concentrations
of Ch-HA NPs: (I) cell viability, (II) cell proliferation and (III) total protein synthesis after 1, 2, 3, and 7 days of culture. Asterisk (*) denotes
signiﬁcant diﬀerences (p < 0.01) compared to the control (0 μg/mL).
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biofunctionalization, at a concentration of 50 μg/mL (Figure
4C). Comparing the results of the samples with NPs to the
control, it seems that the hACs do not internalize NPs.
Taking into account the previous results, for THP-1 cell line
(Figure 3B and 4B) and human primary macrophages (Figure
3C) three diﬀerent NPs concentrations (25, 50, and 100 μg/
mL) were tested. Since there were no signiﬁcant diﬀerences
between the NPs and the control, it can be concluded that the
NPs are not cytotoxic at these concentrations for those cells.
Evaluation of IL-6 Capture by Biofunctionalized NPs and
Its Biologic Eﬀects. To conﬁrm the capacity of the primary
anti-IL-6 antibody immobilized at the NPs’ surface to capture
and neutralize IL-6, hACs were stimulated with macrophage
conditioned medium containing 500 pg/mL of IL-6, for 24 h.
Then, three diﬀerent conditions were tested: (1) hACs without
treatment (no treat), (2) treatment with biofunctionalized NPs
(NPs + Ab), and (3) treatment with soluble anti-IL-6 antibody
(Ab). hACs cultured without macrophage conditioned medium
were used as controls (Ctr).
Regarding the amount of unbound IL-6 in the medium
(Figure 5A), the results showed that macrophage conditioned
medium had a huge impact on IL-6 production by cells, which
corroborates the susceptibility to inﬂammation of hACs isolated
from osteoarthritic patients. These cells produce around 8 ng/
mL of IL-6 without any stimulus. Given the macrophage
conditioned medium, they increased in 85 to 190 times the
amount of this cytokine (0.68 to 1.51 μg/mL at 1 and 14 days,
respectively). Moreover, there was a higher reduction of free
IL-6 in the medium with biofunctionalized NPs comparing to
the soluble antibody. Therefore, the results conﬁrmed the initial
hypothesis that the primary antibody immobilized at the NPs’
surface had a longer eﬀect than the soluble antibody.
After hACs stimulation with macrophage conditioned
medium there was a signiﬁcant decrease in cell viability and
DNA concentration comparatively to the control (Figure 5B
and C). Alternatively, the condition with biofunctionalized NPs
had an improvement in cell viability and proliferation, since
there was no signiﬁcant diﬀerence when compared with the
control. Furthermore, this improvement was signiﬁcantly higher
in comparison with the soluble antibody, especially at 7 and 14
days. Despite these results, total protein concentration was
almost the same for all conditions under evaluation (Figure
5D).
The analyses of cell morphology (Figure 6) revealed that the
stimulated cells showed altered morphology with cell shrinkage,
especially after 14 days. As shown in Figure 6, hACs remained
widely normal with the addition of functionalized NPs, while
the addition of soluble antibody did not prevent cell shrinkage.
■ DISCUSSION
The aim of this study was to develop a carrier intended for local
administration and allowing the capture and inactivation of a
central pro-inﬂammatory mediator, IL-6, in arthritic joints. Ch
and HA polysaccharides were used as the NPs building blocks.
The backbone of Ch consists of glucosamine units, which has a
high density of NH2 (pKa ≈ 6.5), giving to Ch its cationic
nature. This property allows Ch to electrostatically bind with
Figure 4. SEM micrographs of Ch-HA NPs cultured with (A) hACs or (B) THP-1 cells in the absence (control, I) and in the presence of NPs at
diﬀerent concentrations: (II) 20, (III) 50, and (IV) 100 μg/mL. Confocal microscopy images of hACs (C): (I) control, (II) NPs, and (III)
biofunctionalized NPs, being the NPs green (FITC), nuclei blue (DAPI), and the cytoskeleton red (phalloidin).
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Figure 5. Biochemical performance of the stimulated hACs: (1) without stimulation (Ctr), (2) hACs without treatment (no treat), (3) treatment
with biofunctionalized NPs (NPs + Ab), and (4) treatment with soluble antibody (Ab), and analyzed regarding (A) unbound IL-6 concentration,
(B) cell viability, (C) cell proliferation, and (D) total protein synthesis. a denotes signiﬁcant diﬀerence (p < 0.01) compared to the Ctr, and b
denotes signiﬁcant diﬀerence (p < 0.01) compared to NPs + Ab.
Figure 6. SEM micrographs of stimulated hACs: (A) control without stimulation, (B) stimulation without treatment, (C) biofunctionalized NPs,
and (D) soluble Ab after 14 days of culture. Micrographs obtained after 7 days of culture are shown to evaluate the eﬀect during time (small images).
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negatively charged molecules. HA is an anionic biopolymer
containing glucuronic acid with COOH as functional groups
(pKa 3−4), at a proportion of 1:2 comparing to NH2 of Ch.
These two functional groups were used to produce NPs by
polyelectrolyte complexation. As in the literature,27,28 the initial
polymer concentrations were optimized according to the
experimental conditions and the aim of the work. Therefore,
we selected 0.25, 0.5, and 1 mg/mL. The concentration of Ch
and HA was observed to aﬀect the size and PDI of the resulting
NPs. Additionally, diﬀerent initial pH of the polymers solutions
was tested to evaluate the impact of the protonation/
deprotonation of NH2 and COOH groups on the properties
of the NPs. Indeed, the pH of the Ch solution has a strong
impact in the particle size. NH2 groups of Ch are protonated at
pH 5, NH3
+, which is necessary to interact with COOH groups
of the HA that are deprotonated at pH 5 (COO−). Therefore,
at pH 5 electrostatic interactions between the opposite charges
can be established, resulting in NPs formation.29 However,
those interactions are a reversible physical cross-linking.
Consequently, due to the electrostatic interactions weakness
of the NPs taking place at pH 7.4 (physiological pH) there is an
increase of the NPs size.
Hence, cross-linkers are essential to increase pH stability and
mechanical strength.30 In this work, EDC/NHS were used to
catalyze the reaction between the NH2 of Ch and the COOH
of HA to form amide bonds.31 The resulting NPs were stable at
physiological pH, even after 24 h at 37 °C. This chemical
reaction does not represent a problem in terms of cytotoxicity,
since EDC/NHS chemistry is a zero-length cross-linker.32
Additionally, the only byproduct of the reaction, urea, is
nontoxic, and as all products are water-soluble they are easily
removed in the washing steps. Therefore, an absence of
cytotoxicity is expected. Indeed, several works have being
demonstrated the in vitro and in vivo cytocompatibility of
EDC/NHS chemistry.33
Stable NPs with 121.8 ± 2.4 nm of diameter, 0.11 ± 0.01 of
PDI, and +25.12 ± 1.86 mV of zeta potential were produced
with 0.25 mg/mL of concentration of the initial polymers
solutions, at pH 5, and with 50/200 mM of EDC/NHS
concentration, after their centrifugation with glucose. NPs size
and PDI signiﬁcantly increased without the addition of this
sugar to the NPs suspension. As reported for lyophilization,34
the centrifugation with glucose leads to the development of a
layer around the NPs in the pellet, avoiding their aggregation
when resuspended. From these results, it can be inferred that
the NPs suspension are homogeneous in terms of size, since
typically monodisperse suspensions have PDI values less than
0.2.35 As expected from the ratio of NH2/COOH (2:1), the
zeta potential of the produced NPs was positive. Recent reports
have been described that cationic proteins and particles increase
the retention of therapeutic agents in articular joints.36,37
Hence, it will be expectable higher retention in the target tissue
of the developed NPs. Moreover, the value of zeta potential
gives an indication of the NPs suspension stability.38 Higher
absolute values of this parameter, give rise to stronger repellent
electrostatic interactions between the NPs dispersed in water,
which leads to a higher stability of the suspension. Guidelines
classifying NP suspensions with zeta potential values of ±0−10
mV as highly unstable, ±10−20 mV as relatively stable, ±20−
30 mV as moderately stable, and >±30 mV as highly stable.39
Regarding the value obtained around +25 mV, it is possible to
conclude that the NPs are moderately stable. Stability assays
also corroborated the suspension stability, since they showed
that NPs conserved their size distribution for at least 6 months,
under the tested conditions.
After optimization of the process for NPs preparation, anti-
IL-6 antibody was immobilized at their surface using the same
chemistry previously referred. In this case, the COOH groups
of the antibodies reacted speciﬁcally with the NH2 groups
present at the NPs’ surface. The maximum concentration of
antibody immobilized by NPs was obtained when it was used
an initial anti-IL-6 antibody concentration of 10 μg/mL. After
this point, the values of the antibody immobilization reached a
plateau, and despite the increment of antibody concentration,
no signiﬁcant diﬀerences were observed in its quantity on the
NPs’ surface. Moreover, it can be concluded that the
immobilization of the antibody at the NPs’ surface did not
aﬀect signiﬁcantly the NPs properties.
Since the goal of the present study was to produce NPs for
IL-6 neutralization, after the primary antibody immobilization,
the cytokine capture capacity was assessed. The maximum
binding ability was obtained for an initial concentration of
antibody of 10 μg/mL, which corresponds to the capture of
1.22 ± 0.02 μg/mL of the protein added (1.25 μg/mL).
Despite the increment of the anti-IL-6 antibody concentration
added to the NPs suspension, the biofunctionalized NPs
neutralized equivalent amounts of the cytokine, which
corroborates the maximum immobilization capacity of the
anti-IL-6 antibody at NPs’ surface, obtained for an initial
antibody concentration of 10 μg/mL.
To use Ch-HA NPs as a platform to treat arthritic diseases,
an assessment of their potential toxicity for both chondrocytes
and immune cells was performed. Ch-HA NPs in a
concentration until 50 μg/mL did not present toxicity for
hACs, THP-1 cells and human primary macrophages. For the
hACs, higher amounts of NPs (10−500 μg/mL) were assessed
and besides none of the concentrations had a huge impact in
cell viability, for concentrations higher than 50 μg/mL, the cell
proliferation was negatively aﬀected. These results can be
explained by analyzing SEM micrographs, where it can be seen
that at higher concentrations, the NPs form agglomerates
around hACs that can inhibit cell spreading. Concerning the
immune cells, the Ch-HA NPs were not cytotoxic under the
tested conditions (25, 50, and 100 μg/mL). In summary, it is
possible to conclude that Ch-HA NPs are cytocompatible for
concentrations up to 50 μg/mL.
Since inﬂammation had an important role in the pathological
process of these diseases, it was investigated if the
biofunctionalized NPs could avoid the negative impact of
inﬂammation into human chondrocytes. hACs were stimulated
with macrophage conditioned medium and three diﬀerent
conditions were tested: (1) hACs without treatment, (2)
treatment with biofunctionalized NPs presenting a concen-
tration of anti-IL-6 antibody equal to 1 μg/mL, and (3)
treatment with soluble anti-IL-6 antibody at a concentration of
1 μg/mL. hACs cultured without macrophage conditioned
medium (only culture medium) were used as controls (Ctr).
The IL-6 of the conditioned media was quantiﬁed in order to
ensure the presence of 500 pg/mL of IL-6, which is within the
range of the IL-6 levels found in the synovial ﬂuid of OA and
RA patients (119.4 ± 193.2 and 354.7 ± 1851.6 pg/mL,
respectively).40 This experiment showed that the macrophage
conditioned medium has a huge impact in the hACs production
of IL-6, since they increase in 85−190 times the amount of IL-
6, when compared to the control. Additionally, it corroborates
the susceptibility to inﬂammation of hACs isolated from
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osteoarthritic patients. The reduction of the interleukin amount
obtained in the conditions with biofunctionalized NPs or with
soluble antibody conﬁrms the neutralization of IL-6 by the
primary antibody, and consequently the reduction of its
negative eﬀects. Moreover, there was a higher reduction of
IL-6 in the medium with biofunctionalized NPs comparing to
the soluble antibody, which conﬁrmed the initial hypothesis
that the primary antibody immobilized at the NPs’ surface had
a longer eﬀect than the soluble antibody.
A previous study demonstrated that the synovial ﬂuid
obtained from OA and RA patients led to altered cell
morphology, to a highly signiﬁcant decrease of vital
chondrocytes and also activates the synthesis of pro-
inﬂammatory cytokines in primary human chondrocytes.41 In
the present work, we used macrophage conditioned medium to
stimulate hACs, and observed similar eﬀects, since there was a
signiﬁcant decrease in cell viability and DNA concentration,
and cell morphology shift in the stimulation condition. Since
the addition of the biofunctionalized NPs was able to reduce
these eﬀects (more than the free antibody), it was
demonstrated that the antibody immobilized at the NPs’
surface has a prolonged action and stronger eﬃcacy than the
free antibody. The antibody immobilization can increase its
stability and reduce its degradation, explaining the prolonged
eﬀect observed. Therefore, the conjugation of antibodies to
NPs combines the advantages of NPs support, with lower
degradability, and longer half-life time and eﬃcacy of the
antibodies. Moreover, they retain the speciﬁc and selective
recognition of the antigens to capture and neutralize them.42
In a recent study, anti-IL-6 antibodies were encapsulated into
poly(lactic-co-glycolic acid) NPs to antagonize the eﬀect of IL-6
locally in the heart, as a therapeutic procedure to prevent/
ameliorate organ ischemia−reperfusion injury.43 The localized
delivery of anti-IL-6 signiﬁcantly reduced immune rejection of
transplants with a lower amount administered, comparing with
the systemic delivery. In this context, the covalent immobiliza-
tion of anti-IL-6 into Ch-HA NPs’ surface can be a viable and
eﬀective strategy to increase the antibody eﬃcacy when injected
locally in joint cavities, which can reduce the dosage and
signiﬁcantly avoid associated systemic side eﬀects.
Although the controversy about the size necessary to retain
longer the particles in the joint cavity, preclinical studies clearly
demonstrate that NPs can be eﬀective for IA delivery.44 The
prescribed dose of anti-IL-6 in RA patients (for OA patients is
not yet an available therapy) is around 8 mg/kg IV, which can
be dramatically reduced using this system injected IA. Indeed,
with 1 μg/mL of antibody immobilized in NPs the
inﬂammatory scenario was signiﬁcantly reduced. Furthermore,
as the NPs are composed of well-known biodegradable
polymers, they can be further degraded by biological processes,
without any toxic eﬀects for the cells, enabling subsequent
treatments.
■ CONCLUSION
In the present work, we developed natural biodegradable
polymeric NPs biofunctionalized with anti-IL-6 antibodies able
to selectively capture and inactivate the pro-inﬂammatory
cytokine IL-6. Because of the key role of IL-6 in arthritis, its
eﬀective neutralization by the NPs will reduce inﬂammation,
leading to a possible decrease of swelling and pain in such
diseases.
Current treatments present serious side eﬀects and limited
eﬃcacy mainly because of the rapid clearance of antibodies by
the body. Presently, to have an improvement in arthritis, higher
doses, and extended periods of treatments are needed.
Therefore, it is foreseeable that the developed NPs will
overcome the limitations of the above-mentioned treatments,
since they will increase the antibodies therapeutic eﬃcacy as a
result of their subcellular size, cytocompatibility, high
functionalization, and stability, avoiding associated side eﬀects.
Indeed, these systems have enhanced eﬃcacy and prolonged
action in the capture and neutralization of IL-6 when compared
with the free antibody.
In conclusion, the biofunctionalized NPs are a valid approach
for the local and sustained treatment of inﬂammatory arthritic
diseases. Hence, the outcomes of this work have important
implications for increasing the eﬃcacy of currently available
treatments, by prolonging the therapeutic action of the
antibodies and avoiding most of their side eﬀects. Those
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